MK2206, an orally available allosteric inhibitor of Akt, is being used to treat patients with advanced breast cancer (http://clinicaltrials.gov/show/NCT01277757), and AZD5363, a novel orally available Akt inhibitor, is being used in the treatment of patients with phase I advanced or metastatic breast cancer and phase II ER-positive advanced or metastatic breast cancer (http://clinicaltrials.gov/show/NCT01625286). This evidence concerns the gene AKT1 and breast carcinoma.